OK-POWER-COSTS-INC
23.6.2020 10:02:16 CEST | Business Wire | Press release
RWE Renewables, one of the world’s largest owners of renewable energy projects and the newest subsidiary of Germany’s RWE Group, has selected PCI’s Enterprise Platform for its marketing and trading requirements in six U.S. power markets (ERCOT, ISO New England, MISO, New York ISO, PJM, and SPP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200623005287/en/
As part of the partnership with RWE Renewables, PCI will deploy its specifically tailored, multi-market, cloud-based, integrated platform to replace RWE’s legacy system and several in-house applications. A phased implementation will cover the following key RWE requirements:
- Complete Bid-to-Bill workflow management and automation
- Deal Management, Trading, and REC Management
- Contract Settlements and Meter Data Management
- eTagging
- Outage Management
Christoph Hunfeld, RWE’s Senior Vice President of Asset Commercialization in North America noted, “After an extensive evaluation process, we selected PCI to be our long-term technology partner based on their expertise, solution coverage, and experience with multiple successful go-lives in various markets.”
"PCI is proud to welcome RWE as one of its premier global enterprise customers,” said PCI Vice President Shailesh Mishra. “The majority of large, global renewable power companies, utilities and trading houses rely on our technology platform for their mission-critical operations.”
The PCI Platform offers unmatched functionality for renewable energy players to optimize their portfolios, including co-optimization of Energy Storage Systems in ISO/RTO markets. PCI works with numerous renewable energy providers including, Xcel Energy, Iberdrola, Acciona, BHE Renewables, CPS Energy, and others.
About RWE Renewables
RWE Renewables, the newest subsidiary of the RWE Group, is one of the world's leading renewable energy companies. Following the completion of the transaction with E.ON, RWE Renewables has onshore and offshore wind farms, photovoltaic plants and battery storage facilities with a combined capacity of more than 9 gigawatts. The company is driving the expansion of renewable energy in more than 20 countries on four continents. For further growth an annual investment budget of €1.5 billion net is available. When adding in possible partnerships, the investment budget could increase to between €2 and €3 billion per annum. The focus is on the Americas, the core markets in Europe and the Asia-Pacific region. To learn more, please visit www.rwe.com/usa .
About Power Costs, Inc. (PCI)
PCI is the leading provider of mission critical software, superior customer support and value-added services for energy companies worldwide. Founded in 1992, PCI continues to refine and develop new software solutions that meet the ever-evolving needs of its clients which include renewable energy companies, investor-owned, municipal and cooperative utilities, energy marketers and traders, as well as independent power producers. More than half the power generated in North America is optimized using the PCI Platform and over 60% of the Fortune 500 Utilities in the U.S. are PCI clients. The firm is privately held and based in Norman Oklahoma with offices in Houston (TX), Raleigh (NC) and Mexico City. To learn more about PCI, please visit www.powercosts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom